TOP TEN perturbations for 40036_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40036_at
Selected probe(set): 210093_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40036_at (210093_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample
Relative Expression (log2-ratio):-3.530717Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal T-cell sample |
| MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)
Relative Expression (log2-ratio):-3.2772408Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal T-cell; 20uM) |
| MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):-2.3711061Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal B-cell sample |
| MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
glioma study 27 (glioblastoma, NOS) / glioma study 27 (pilocytic astrocytoma)
Relative Expression (log2-ratio):2.250123Number of Samples:4 / 2
| Experimental | glioma study 27 (glioblastoma, NOS) |
| Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma). | |
| Control | glioma study 27 (pilocytic astrocytoma) |
| Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma). |
nephroblastoma study 2 / normal kidney tissue (adult)
Relative Expression (log2-ratio):2.2474613Number of Samples:4 / 3
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
scleroderma study 8 (blood; anifrolumab; 1mg/kg/wk; multiple dose; 56d) / scleroderma study 8 (blood; baseline; 1mg/kg/wk; multiple dose)
Relative Expression (log2-ratio):2.1437502Number of Samples:4 / 4
| Experimental | scleroderma study 8 (blood; anifrolumab; 1mg/kg/wk; multiple dose; 56d) |
| Whole blood samples collected from adult systemic sclerosis patients at day 56 after a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1. ATC code:--- | |
| Control | scleroderma study 8 (blood; baseline; 1mg/kg/wk; multiple dose) |
| Whole blood samples from adult systemic sclerosis patients before a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):-2.0436182Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):1.9410973Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
diabetes type 2 study 14 (diabetic) / non-diabetic omental adipose tissue
Relative Expression (log2-ratio):-1.9072552Number of Samples:11 / 6
| Experimental | diabetes type 2 study 14 (diabetic) |
| Omental adipose tissue of morbidly obese (BMI ≥ 40 kg/m2) African-American individuals with type 2 diabetes. | |
| Control | non-diabetic omental adipose tissue |
| Omental adipose tissue of morbidly obese (BMI ≥ 40 kg/m2) African-American individuals without type 2 diabetes. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):1.8249245Number of Samples:2 / 2
| Experimental | T-cell activation study 1 |
| CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
| Control | quiescent CD4+ T-cell sample |
| Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |